Biocan Novel DHPPI/L4R 10 doses
Biocan Novel DHPPI/L4R 10 doses
Canine live vaccine against parvovirosis, distemper,inf. hepatitis, inf. laryngotracheitis and parainfluenza and inactivated liquid vaccine against four serovars of leptospirosis and rabies. Vaccine for active immunization of dogs from 8-9 weeks of age.
Composition per 1 ml dose
Lyophilisate (live attenuated):
Canine Distemper virus, strain CDV Bio 11/A- min.103.1 TCID50*, max. 105.1 TCID50*
Canine Adenovirus Type 2, strain CAV-2 Bio 13 - min. 103.6 TCID50* , max. 105.3 TCID50*
Canine Parvovirus Type 2b, strain CPV-2b Bio 12/B - min. 104.3 TCID50* , max. 106.6 TCID50*
Canine Parainfluenza Type 2 virus, strain CPiV-2 Bio 15 - min. 103.1 TCID50*, max. 105.1 TCID50*
Leptospira interrogans serogroup icterohaemorrhagiae serovar icterohaemorrhagiae, strain MSLB 1089 GMT** ≥ 1:51 ALR***
Leptospira interrogans serogroup canicola serovar canicola, strain MSLB 1090 GMT** ≥ 1:51 ALR***
Leptospira kirschneri serogroup grippotyphosa serovar grippotyphosa, strain MSLB 1091 GMT** ≥ 1:40 ALR***
Leptospira interrogans serogroup australis serovar bratislava, strain MSLB 1088 GMT** ≥ 1:51 ALR***
Inactivated rabies virus, strain SAD Vnukovo-32 > 2.0 IU****
Adjuvant: aluminium hydroxide (quantified as Al2O3) 1.8-2.2 mg
* Tissue culture infectious dose – 50%
** Antibody micro agglutination-lytic reaction (serology in rabbits)
*** Geometric mean titre
**** International Units;
Lyophilisate and solvent for suspension for injection.
Lyophilisate: Spongy matter, white colour.
Solvent: Pink liquid with easily shakeable sediments.
Indications for use
Active immunization of dogs from 8-9 weeks of age.
to prevent mortality and clinical signs caused by canine distemper virus
to prevent mortality and clinical signs caused by canine adenovirus type 1
to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2
to prevent clinical signs, leukopenia and viral excretion caused by canine parvovirus
to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus
to prevent clinical signs, infection and urinary excretion caused by L. interrogans serogroup Australis serovar Bratislava
to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae
to prevent clinical signs and reduce infection and urinary excretion caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa
to prevent mortality, clinical signs and infection caused by rabies virus
Onset of immunity:
- 2 weeks after a single vaccination from 12 weeks of age for rabies,
- 3 weeks after the first vaccination for CDV, CAV, CPV,
- 3 weeks after completion of the primary course for CPiV and
- 4 weeks after completion of the primary course for Leptospira components.
Duration of immunity:
At least three years following the primary vaccination course for canine distemper virus, canine adenovirus type 1, canine adenovirus type 2, canine parvovirus and rabies. At least one year following the primary vaccination course for canine parainfluenza virus, Leptospira components. Duration of immunity for rabies was demonstrated after one vaccination at 12 weeks of age.
The duration of immunity against CAV-2 was not established by challenge. It was shown that 3 years after the vaccination CAV-2 antibodies are still present. Protective immune response against CAV-2 associated respiratory disease is considered to last at least 3 years.
Do not use in case of hypersensitivity to the active substance, to the adjuvant or to any of the excipients.
Special warning for each target species
A good immune response is reliant on a fully competent immune system. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.
Immunological responses to the CDV, CAV-2 and CPV components of the vaccine may be delayed due to maternally derived antibody interference. However, the vaccine has been proven to be protective against virulent challenge in the presence of maternally derived antibodies to CDV, CAV and CPV at levels equal or higher to those likely to be encountered under field conditions. In situations where very high maternally derived antibodies levels are expected, the vaccination protocol should be planned accordingly.
Special precautions for use
Special precautions for use in animals:
Only clinically healthy animals should be vaccinated.
Do not use in animals that are showing signs of rabies or that are suspected of being infected with rabies virus.